Just a small bit of info relating to the possibilities ref "Big Pharma Deals"
Here is some stuff about a company called KITE PHARMA
I'm not qualified to make comment as to the difference between exactly what IMU are doing and others ( ie Kite Pharma - as mentioned below ) Nor can I comment on the state of advancement between Kite & IMU
Please see
a) the link to Kite Pharma & their recently announced results over a therapy - I'm not sure if its a "T Cell" therapy or not ( others might )
https://www.telegraph.co.uk/science...patients-complete-remission-one-gene-therapy/
Note there are reservations about this treatment .
b) The link to an article about someone buying out / taking over Kite
http://fortune.com/2017/08/28/gilead-kite-pharma-stock/
Note the potential worth is quite large , and the numbers quite huge
Comment :
IF IMU have the goods - there is every reason to be quite optimistic about upside . Not just a piddly 100% - 500 % off the current base .
Would really like some one like Leslie Chan to comment on Kite Pharma & if this article has relevance to IMU
Meanwhile .....refer to a snippet form ASX Announcement Feb 12 2018
Leslie's words have been to describe the "b cell " approach as ....read the last paragraph below .
The concept of teaching and inducing the body to generate its own antibodies against PD-1 expressing cells represents a paradigm shift in immuno-oncology, and is the first report of treating cancer by this method.
A new method of treatment patent (Australian Patent Office: 2018900368) has been filed to provide protection across a broad landscape of possible immunotherapies, including their combination with cancer vaccines such as HER-Vaxx. Imugene will now commence a preclinical development program which will test the vaccine for both efficacy and safety. This program will be intensive yet systematic to yield a clinical-ready vaccine candidate.
Professor Dr Ursula Wiedermann and Imugene CEO Leslie Chong said in a joint announcement “Development of this new immunotherapy has positioned Imugene to be a new and competitive player in the immuno-oncology revolution in cancer therapy.This expands our pipeline and transforms Imugene into a multi-asset biopharmaceutical company.”
Leslie Chong added “On announcing our mimotope program in January 2016 we were cautious given the early stage of the research. However, the progress made by the entire team raises the anticipation that a paradigm shift in cancer treatment is in play.”
2018 will be a very interesting year
LOL
VA
(20min delay)